Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 4/20 | 0.38 |
| ▸ | CA1 | P00915 | 4/20 | 0.38 |
| ▸ | CA9 | Q16790 | 4/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.35 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.33 |
| ▸ | PREP | P48147 | 2/20 | 0.33 |
| ▸ | DHFR | P00374 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7706827 | 0.78 | CA1 (0.50) | CA12CA1CA9HSP90AA1HSP90AB1 | |
| SCHEMBL558917 | 0.76 | CA12 (0.41) | CA12CA1CA9HSP90AA1HSP90AB1 | |
| SCHEMBL30556218 | 0.74 | CA12 (0.44) | CA12CA1CA9HSP90AA1HSP90AB1 | |
| SCHEMBL8883542 | 0.74 | CA12 (0.44) | CA12CA1CA9HSP90AA1HSP90AB1 | |
| SCHEMBL190164 | 0.73 | CA12 (0.35) | CA12CA1CA9HSP90AA1HSP90AB1 | |
| SCHEMBL3182564 | 0.73 | CA12 (0.46) | CA12CA1CA9HSP90AA1HSP90AB1 | |
| SCHEMBL5292779 | 0.72 | ACHE (0.45) | CA12CA1CA9MAOB | |
| SCHEMBL4004898 | 0.72 | CYP3A4 (0.47) | CA12CA1CA9HSP90AA1HSP90AB1 | |
| SCHEMBL2329760 | 0.72 | ACHE (0.50) | CA12CA1CA9HSP90AA1HSP90AB1 | |
| SCHEMBL232409 | 0.72 | CA12 (0.45) | CA12CA1CA9HSP90AA1HSP90AB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148415-B2 | Sulfamic acid ester compounds useful in the inhibition of steroid sulphatase activity and aromatase activity | STERIX LIMITED (GB) | 2012-04-03 | — | — | US | disclosed |
| US-8148415-B2 | Sulfamic acid ester compounds useful in the inhibition of steroid sulphatase activity and aromatase activity | STERIX LIMITED (GB) | 2012-04-03 | — | — | US | disclosed |
| US-8148415-B2 | Sulfamic acid ester compounds useful in the inhibition of steroid sulphatase activity and aromatase activity | STERIX LIMITED (GB) | 2012-04-03 | — | — | US | disclosed |
| US-20070213383-A1 | Sulfamic acid ester compounds useful in the inhibition of steroid sulphatase activity and aromatase activity | STERIX LIMITED (GB) | 2007-09-13 | — | — | US | disclosed |
| US-20070213383-A1 | Sulfamic acid ester compounds useful in the inhibition of steroid sulphatase activity and aromatase activity | STERIX LIMITED (GB) | 2007-09-13 | — | — | US | disclosed |
| US-20070213383-A1 | Sulfamic acid ester compounds useful in the inhibition of steroid sulphatase activity and aromatase activity | STERIX LIMITED (GB) | 2007-09-13 | — | — | US | disclosed |
| EP-1765792-A1 | SULFAMIC ACID ESTER COMPOUNDS USEFUL IN THE INHIBITION OF STEROID SULPHATASE ACTIVITY AND AROMATASE ACTIVITY | Sterix Limited (GB) | 2007-03-28 | — | — | EP | disclosed |
| US-20060241173-A1 | A sulfamate compound, especially a sulfamylated flavone, isoflavone or flavanone, that is an inhibitor of both estrone sulfatase activity and aromatase activity for treating breast and endometrial cancers | STERIX LTD. | 2006-10-26 | — | — | US | disclosed |
| WO-2005115996-A1 | SULFAMIC ACID ESTER COMPOUNDS USEFUL IN THE INHIBITION OF SEROID SULPHATASE ACTIVITY AND AROMATASE ACTIVITY | STERIX LIMITED (GB) | 2005-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241173-A1 | A sulfamate compound, especially a sulfamylated flavone, isoflavone or flavanone, that is an inhibitor of both estrone sulfatase activity and aromatase activity for treating breast and endometrial cancers | STS, SULT1E1, CYP19A1 | CA12 1717/4885CA1 741/4885CA9 814/4885 |
| US-20070213383-A1 | Sulfamic acid ester compounds useful in the inhibition of steroid sulphatase activity and aromatase activity | STS, SULT1E1, CYP19A1 | CA12 930/4885CA1 472/4885CA9 378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.